Filtered By:
Drug: Xolair
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1700 results found since Jan 2013.
Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study
The objective of this study is to evaluate the effect of omalizumab as an adjunct to endoscopic sinus surgery (ESS) on the treatment of CRSwNP under real-life conditions.Recent FindingsSince the introduction of omalizumab, as the first biologic agent for the treatment of diseases such as severe allergic asthma, different studies have demonstrated an effect of omalizumab on CRSwNP, with significant improvements in sinonasal symptoms and endoscopic scores. The high efficacy derived from mAb therapy and the need for ESS prior to mAb recommended by guidelines, has led to compare both therapeutic alternatives, finding discrepan...
Source: Current Allergy and Asthma Reports - September 19, 2023 Category: Allergy & Immunology Source Type: research
Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta ‐analysis of randomized controlled trials
ConclusionOmalizumab + AIT can significantly enhance the efficacy and safety of AIT by increasing TMD and SU to allergens, while decreasing severe systemic AEs.
Source: International Forum of Allergy and Rhinology - September 16, 2023 Category: Allergy & Immunology Authors: Ying ‐Ying Zhang,
Min Zhang,
Jia‐Qi Zhang,
Qiu‐Qi Li,
Mei‐Ping Lu,
Lei Cheng Tags: ORIGINAL ARTICLE Source Type: research
Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study
The objective of this study is to evaluate the effect of omalizumab as an adjunct to endoscopic sinus surgery (ESS) on the treatment of CRSwNP under real-life conditions.Recent FindingsSince the introduction of omalizumab, as the first biologic agent for the treatment of diseases such as severe allergic asthma, different studies have demonstrated an effect of omalizumab on CRSwNP, with significant improvements in sinonasal symptoms and endoscopic scores. The high efficacy derived from mAb therapy and the need for ESS prior to mAb recommended by guidelines, has led to compare both therapeutic alternatives, finding discrepan...
Source: Current Allergy and Asthma Reports - August 30, 2023 Category: Allergy & Immunology Source Type: research
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
While both the AAAAI/ACAAI and the EAACI/GA2LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinician...
Source: Allergy, Asthma and Clinical Immunology - August 29, 2023 Category: Allergy & Immunology Authors: Anthony F. LaCava and Olajumoke O. Fadugba Tags: Case report Source Type: research
Retrospective Analysis and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
Monoclonal antibodies (MAbs), including omalizumab, mepolizumab, benralizumab and dupilumab revolutionized severe asthma therapy. Each MAb is effective, none clearly superior.1 –3 Nonetheless, many patients switch MAbs due to insufficient response, side effects or to treat comorbidities. Switching MAbs often improves asthma, yet the frequency, causality and outcome of switches remain understudied.4–6 Thus, universal, standardized responder criteria are needed. “Biolo gics Asthma Response Score” (BARS) combines asthma control test, daily oral corticosteroid dose and annualized exacerbation rate, using a scoring syst...
Source: Annals of Allergy, Asthma and Immunology - August 12, 2023 Category: Allergy & Immunology Authors: Moritz Z. Kayser, Ben L. J ülicher, Tobias Welte, Jan Fuge, Hendrik Suhling Tags: Letters Source Type: research
Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
Monoclonal antibodies (MAbs), including omalizumab, mepolizumab, benralizumab, and dupilumab, revolutionized severe asthma therapy. Each MAb is effective, none clearly superior.1 –3 Nonetheless, many patients switch MAbs owing to insufficient response or adverse effects, or to treat comorbidities. Switching MAbs often improves asthma, yet the frequency, causality, and outcome of switches remain understudied.4–6 Thus, universal, standardized responder criteria are needed. “Biologics Asthma Response Score” (BARS) combines asthma control test, daily oral corticosteroid dose, and annualized exacerbation rate, using a s...
Source: Annals of Allergy, Asthma and Immunology - August 12, 2023 Category: Allergy & Immunology Authors: Moritz Z. Kayser, Ben L. J ülicher, Tobias Welte, Jan Fuge, Hendrik Suhling Tags: Letters Source Type: research
Real-world Severe Asthma Biologic Administration and Adherence Differs by Biologic: CHRONICLE Study Results
CONCLUSION: Patients with SA are mostly adherent to biologic therapies. Biologics with shorter dosing intervals and at-home administration had worse adherence, likely due to greater opportunities for delays. Specialist-reported administration data provide a unique perspective on biologic adherence, which may be overestimated for at-home administrations by insurance claims data.PMID:37506846 | DOI:10.1016/j.anai.2023.07.017
Source: Annals of Allergy, Asthma and Immunology - July 28, 2023 Category: Allergy & Immunology Authors: Dennis K Ledford Weily Soong Warner Carr Jennifer Trevor Laren Tan Donna Carstens Christopher S Ambrose Source Type: research
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents ’ efficacy
ConclusionsAlthough the present analysis showed a moderate supremacy of dupilumab, there is still no evidence-based answer to the question “which biologic agent is the most effective in CRS treatment?” Improved statistical methodology, head-to-head trials, and real-life studies could lead to more robust conclusions, establishing the real role of the specific biologic agents.
Source: International Forum of Allergy and Rhinology - July 19, 2023 Category: Allergy & Immunology Authors: Georgios X. Papacharalampous,
Jannis Constantinidis,
George Fotiadis,
Nan Zhang,
Claus Bachert,
Michael Katotomichelakis Tags: REVIEW ARTICLE Source Type: research
Update on oral and epicutaneous immunotherapy for children with food allergy
ConclusionThe implementation of recent treatment protocols has significantly improved the safety of OIT. Therefore, its continuation using safety protocols can be considered in the selection of the optimal OIT for individual patients, as provision of safe and effective treatment is crucial for the success of OIT.
Source: Allergo Journal International - July 11, 2023 Category: Allergy & Immunology Source Type: research
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) treated with omalizumab, dupilumab or mepolizumab: review of the current knowledge towards an attempt to compare agents ’ efficacy – A systematic review
ConclusionsAlthough the present analysis showed a moderate supremacy of dupilumab, there is still no evidence-based answer to the question “which biologic agent is the most effective in CRS treatment?” Improved statistical methodology, head-to-head trials and real-life studies could lead to more robust conclusions, establishing the real role of the specific biologic agents.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - July 3, 2023 Category: Allergy & Immunology Authors: Georgios X. Papacharalampous,
Jannis Constantinidis,
George Fotiadis,
Nan Zhang,
Claus Bachert,
Michael Katotomichelakis Tags: REVIEW ARTICLE Source Type: research
Marginal Zone
Cartootorial: Food-allergic patients often experience anxiety about the possibility of a life-threatening reaction from an accidental exposure.1 While FDA-approved therapies to prevent this remain limited, anti-IgE biologics have shown promise for this indication.1,2,3 As monotherapy, omalizumab and a similar drug, TNX-901, significantly increased the reaction threshold in peanut-allergic patients from
Source: Annals of Allergy, Asthma and Immunology - June 30, 2023 Category: Allergy & Immunology Authors: Erin L. Reigh Tags: Marginal Zone Source Type: research
Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial
Source: Journal of Asthma and Allergy - June 24, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Updates in the Role of Biologics in Asthma
AbstractPurpose of ReviewThe purpose of this review is to provide an update on the current biologic treatments available for severe asthma, focusing on the mechanism and clinical efficacy of each agent. Prior to the FDA approval for biologic agents, patients diagnosed with severe asthma frequently depended on the use of systemic steroids in order to control their disease. Since the introduction of first approved biologic for IgE-mediated asthma, other biologic agents surfaced and are now available for other asthma phenotypes.Recent FindingsIn addition to omalizumab, which targets IgE-mediated asthma, there are now multiple...
Source: Current Treatment Options in Allergy - June 20, 2023 Category: Allergy & Immunology Source Type: research
